Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza Hemagglutinin Glycoprotein (HA)
- Target
- HA
- Molecular classification
- Glycoprotein, Viral protein, Membrane protein, Fusion protein, Receptor
01
Overview
Influenza hemagglutinin glycoprotein is a trimeric class I fusion protein crucial for both attachment to host cell receptors via sialic acids and subsequent membrane fusion during infection. Its structure comprises variable head domains targeted by immunity/vaccines and more conserved stalk regions. Antigenicity shifts through mutations/glycan changes drive ongoing challenges in vaccine design due to rapid evolution under immune pressure.
- Other names
- HemagglutininHA proteinInfluenza HA
02
Mechanism of action
Antibodies bind to HA, preventing receptor binding and/or membrane fusion. Vaccines induce antibody production. Experimental fusion inhibitors directly block HA-mediated membrane fusion.
03
Biological functions
Receptor bindingMembrane fusionViral entryHost cell attachmentAntigen presentation
04
Disease associations
InfectionInfluenzaViral pathogenesis
05
Safety considerations
Antigenic drift (requires vaccine updates)Antigenic shift (potential for pandemics)Antibody-dependent enhancement (ADE) - theoretical risk with some antibody therapiesZoonotic transmission (risk of novel HA subtypes emerging from animal reservoirs)
06
Interacting drugs
NA inhibitors (e.g., Oseltamivir, Zanamivir) - indirectly impact HA function by preventing viral release
3 more in the full profile.
07
Biomarkers
HA titer (for vaccine efficacy)HA sequence variants (for strain typing and vaccine matching)Antibody titers against specific HA subtypes
Beyond the preview
Go deeper on Influenza Hemagglutinin Glycoprotein (HA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza Hemagglutinin Glycoprotein (HA).